- Home
- RBOT vs ASRT Comparison
RBOT vs ASRT Comparison
Compare RBOT & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- ASRT
- Stock Information
- Founded
- RBOT 2014
- ASRT 1995
- Country
- RBOT United States
- ASRT United States
- Employees
- RBOT N/A
- ASRT N/A
- Industry
- RBOT Medical Specialities
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- ASRT Health Care
- Exchange
- RBOT Nasdaq
- ASRT Nasdaq
- Market Cap
- RBOT 86.1M
- ASRT 85.1M
- IPO Year
- RBOT N/A
- ASRT 1997
- Fundamental
- Price
- RBOT $15.85
- ASRT $0.83
- Analyst Decision
- RBOT Hold
- ASRT Strong Buy
- Analyst Count
- RBOT 2
- ASRT 4
- Target Price
- RBOT $10.25
- ASRT $3.19
- AVG Volume (30 Days)
- RBOT 52.5K
- ASRT 634.7K
- Earning Date
- RBOT 03-03-2025
- ASRT 03-10-2025
- Dividend Yield
- RBOT N/A
- ASRT N/A
- EPS Growth
- RBOT N/A
- ASRT N/A
- EPS
- RBOT N/A
- ASRT N/A
- Revenue
- RBOT N/A
- ASRT $125,763,000.00
- Revenue This Year
- RBOT N/A
- ASRT N/A
- Revenue Next Year
- RBOT N/A
- ASRT $1.84
- P/E Ratio
- RBOT N/A
- ASRT N/A
- Revenue Growth
- RBOT N/A
- ASRT N/A
- 52 Week Low
- RBOT $4.27
- ASRT $0.73
- 52 Week High
- RBOT $19.00
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- RBOT 59.59
- ASRT 42.81
- Support Level
- RBOT $12.03
- ASRT $0.78
- Resistance Level
- RBOT $15.25
- ASRT $0.94
- Average True Range (ATR)
- RBOT 2.06
- ASRT 0.05
- MACD
- RBOT 0.05
- ASRT -0.00
- Stochastic Oscillator
- RBOT 56.49
- ASRT 29.56
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.